Jeff Glajch
Analyst · Circle N Advisors. Please proceed with your question
Thank you, Karen, and good morning everyone. If I could – have you turned to Slide 4? Q4 sales grew 7% to $23.6 million. In the quarter, we had a net loss of $4.6 million, which is primarily due to an impairment charge of $5.3 million related to our commercial nuclear utility business, which we've decided to divest. We've initiated the process and are in serious negotiations with a potential buyer. Excluding the impairment charge, we had net income of $800,000, or $0.08 per share. Orders in the quarter were $21.6 million yielding a $132.1 million year-end backlog, which while just below the Q3 backlog was easily a record for year-end backlog. For the full year, revenue grew 18% to $92 million. Full year net income was a small loss of $300,000, but was a $5 million of income when excluding the aforementioned impairment charge. Orders for the year were just above $101 million, and again, the backlog at the end of the year at $132 million. On to Slide 5. Q4 earnings were similar to the same quarter last year with a 7% higher sales offset by lower gross margins, about 210 basis points below last year's Q4. The lower margins was primarily due to the commercial nuclear utility business as well as one China project. Sales in the quarter were 70% domestic, 30% international, which compares to 66% domestic and 34% international last year. The similar EBITDA and EPS numbers are adjusted for the impairment charge. On to Slide 6. For the full year, sales increased to $91.8 million from $77.5 million. Sales were 65% domestic, 35% international, compared with 67% domestic and 33% respectively, last year. As a side note, our commercial nuclear business, which as I mentioned, we're planning to sell, represented above 9% of fiscal year 2019 sales. Gross profit for the year was $21.9 million, up from $17 million, primarily due to higher volume as well as 200 basis points higher gross margin at 23.9%. SG&A was $17.9 million, up from $15.8 million last year as we are investing in our business for future growth. The adjusted EBITDA margin was $7.7 million, up from $5.4 million last year, and the adjusted net income per diluted share or EPS was $0.51 compared with $0.18 last year. If we could move to Slide 7. Our cash position increased $1.3 million in fiscal year 2019 to $77.8 million or $7.90 per share. We had good operating cash flow, paid $3.8 million in dividends and spent $2.1 million in capital spending in the year. In fiscal year 2020, we expect capital spending to be in the $2.5 million to $2.8 million range. Finally, as we look at our balance sheet and our strong cash position, we continue to have our business development team, our management team and our Board focus on the utilizing that balance sheet to opportunistically identify and close on acquisitions, which have both near and long-term benefits to our shareholders. We continue to be excited about the opportunities that we're seeing in our acquisition pipeline. Jim will now Jim will now complete our presentation on fiscal year 2019 and comment on our outlook for fiscal 2020. Thank you.